American Technion Society

Technion’s Nanofiber PPE Sticker Now In Mass Production

The ‘Maya’ sticker, which enhances the protection of surgical masks worn by medical personnel, has gone into mass production at Kibbutz Ein Harod.
13-Aug-2020 2:40 PM EDT, by American Technion Society

Newswise — In late March, the Technion - Israel Institute of Technology announced one of the first personal protective equipment (PPE) developments for protecting medical teams from COVID-19, the disease caused by the SARS-CoV-2 virus. Comprised of a nanofiber sheet, the unique sticker can be easily adhered to a protective mask, significantly improving its effectiveness against the novel coronavirus. With an agreement now in place, mass production of the ‘Maya’ sticker has begun in Israel.

The sticker was developed under the leadership of Professor Eyal Zussman of the Faculty of Mechanical Engineering at the Technion, under the clinical guidance of Professor Samer Srouji, the director of the Maxillofacial Surgery Department, at the Galilee Medical Center in Nahariya.

Prof. Zussman, an expert on the development of nanometer fibers for various uses, mobilized his knowledge to create a sticker based on a nanofiber sheet to improve the protection capability of protective masks against the novel coronavirus. Due to its tiny size – 130 nanometers – the virus can penetrate a standard protective mask, where the pores between fibers are comparatively large, in the order of hundreds of microns. The nanoscale pores of the sticker prevent the virus from penetrating the mask, and the researchers incorporated biocides into the fiber sheet that neutralize trapped viruses within a few seconds.

An important milestone was recently reached with the signing of an agreement between the Technion and the DYKAM printing plant in Kibbutz Ein Harod. The agreement will enable the innovative sticker to be available to medical staff and the general public with exclusivity agreements to countries such as Canada, Japan, and Spain. The product has been approved by the authorities in Israel (Medical Equipment Division of the Ministry of Health), and is expected to be approved by the authorities in the United States (FDA) and Europe (CE) soon.

The agreement with Kibbutz Ein Harod will not only accelerate the availability of Maya to hospitals and the general public, but may provide the DYKAM paper plant with significant business momentum. The factory, established in 1982, produces various paper products, including thermal papers for medical monitors, transportation cards, boarding passcards, leisure and entertainment cards, and more. However, the pandemic has led to severe financial distress. Some of the key markets the plant relies on were hit hard, sales fell by 50%, and about a quarter of the company’s workers were dismissed.

Now, following the commercialization agreement for the manufacturing of the innovative Maya sticker, DYKAM operations will enter high gear. The plant management hopes the new production line will be just the first of many new lines of profit and activity.

For more than a century, the Technion - Israel Institute of Technology has pioneered in science and technology education and delivered world-changing impact. Proudly a global university, the Technion has long leveraged boundary-crossing collaborations to advance breakthrough research and technologies. Now with a presence in three countries, the Technion will prepare the next generation of global innovators. Technion people, ideas and inventions make immeasurable contributions to the world, innovating in fields from cancer research and sustainable energy to quantum computing and computer science to do good around the world.

The American Technion Society supports visionary education and world-changing impact through the Technion - Israel Institute of Technology. Based in New York City, we represent thousands of US donors, alumni and stakeholders who invest in the Technion’s growth and innovation to advance critical research and technologies that serve the State of Israel and the global good. Over more than 75 years, our nationwide supporter network has funded new Technion scholarships, research, labs, and facilities that have helped deliver world-changing contributions and extend Technion education to campuses in three countries.

Filters close

Showing results

110 of 3327
Newswise: How to Keep Children Safe from COVID-19 this Fall
Released: 18-Sep-2020 4:15 PM EDT
How to Keep Children Safe from COVID-19 this Fall
Rush University Medical Center

With the new school year started and autumn approaching, Colleen Nash, MD, MPH, Rush University Medical Center, pediatric infectious disease specialist, answers questions parents may have about keeping children safe from COVID, social distancing in the classroom and celebrating Halloween.

Released: 18-Sep-2020 4:05 PM EDT
Claims circulating on social media stating that the common cold or flu can be mistaken for COVID-19 are misleading

The claims rely on the faulty assumption that there is no method to distinguish COVID-19 from the common cold and the flu.

Released: 18-Sep-2020 3:35 PM EDT
After developing CRISPR test, UConn researchers validate clinical feasibility for COVID-19 testing
University of Connecticut

In March, researchers in the Department of Biomedical Engineering-- a shared department in the schools of Dental Medicine, Medicine, and Engineering--began to develop a new, low-cost, CRISPR-based diagnostic platform to detect infectious diseases, including HIV virus, the novel coronavirus (SARS-CoV-2).

Newswise:Video Embedded blowin-in-the-wind
Released: 18-Sep-2020 3:10 PM EDT
Blowin' in the wind
University of Utah

University of Utah chemical engineers have conducted an air flow study of the venue that the Utah Symphony performs in to determine the best ways to mitigate the spread of COVID-19 through the emissions of wind instrument players.

Newswise: holman1_toned-1-768x512.jpg
Released: 18-Sep-2020 2:50 PM EDT
Study links rising stress, depression in U.S. to pandemic-related losses, media consumption
University of California, Irvine

Irvine, Calif., Sept. 18, 2020 – Experiencing multiple stressors triggered by the COVID-19 pandemic – such as unemployment – and COVID-19-related media consumption are directly linked to rising acute stress and depressive symptoms across the U.S., according to a groundbreaking University of California, Irvine study. The report appears in Science Advances, published by the American Association for the Advancement of Science.

Newswise: 243389_web.jpg
Released: 18-Sep-2020 10:55 AM EDT
Potential new drug to mitigate SARS-CoV-2 infection consequences
University of Malaga

Scientists from the Department of Cell Biology of the University of Malaga (UMA) and the Andalusian Centre for Nanomedicine and Biotechnology (BIONAND) have made progress in finding new rapid implementation therapies to combat the COVID-19 pandemic, identifying a new drug that could prevent or mitigate the consequences derived from SARS-CoV-2 infection.

Newswise: 243400_web.jpg
Released: 18-Sep-2020 10:40 AM EDT
Most homemade masks are doing a great job, even when we sneeze, study finds
University of Illinois at Urbana-Champaign

Studies indicate that homemade masks help combat the spread of viruses like COVID-19 when combined with frequent hand-washing and physical distancing.

access_time Embargo lifts in 2 days
Embargo will expire: 23-Sep-2020 8:00 AM EDT Released to reporters: 18-Sep-2020 10:00 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 23-Sep-2020 8:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 18-Sep-2020 8:30 AM EDT
Immunotherapy Drug Development Pipeline Continues Significant Growth in 2020 Despite Global Pandemic Impact
Cancer Research Institute

Despite the impact of the COVID-19 pandemic across the globe, there has been a resurgence of interest in immuno-oncology (I-O) preclinical and clinical development, bringing hope to cancer patients and physicians who treat them.

Showing results

110 of 3327